Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy

To evaluate the safety of reoperation in patients with renal tumors who have ipsilateral tumor recurrence after nephron-sparing partial nephrectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Robotic Surgical Procedures Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

ipsilateral local rRCC (any recurrence in the ipsilateral kidney and retroperitoneum)

Exclusion criteria

With distant metastasis;
Lacking essential sugery information.

Treatment and study plan

Primary outcomes

Operation time

Time frame: 1 week

Operation time

Secondary outcomes

Estimated blood loss

Time frame: 1 week

Estimated blood loss

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Anhui Medical University

Other

Registry information

Official study title

Reoperation for Ipsilateral Local Recurrence Following Prior Nephron-sparing Surgery: Innovative Surgical Insights From a High-volume Urological Center

Acronym: LiangAH

Important dates

Study start: 2013
Primary completion: 2023
Study completion: 2023
First posted: Mar 19, 2024
Registry last updated: Mar 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed